Zharp1-163
Zharp1-163 is a dual inhibitor of ferroptosis and necroptosis. Zharp1-163 effectively blocks ferroptosis by reducing reactive oxygen species (ROS) levels and inhibits necroptosis by potently and selectively targeting RIPK1 kinase activity (KD = 240 nM; IC50 = 406.1 nM). Zharp1-163 inhibits the cellular activation of RIPK1, RIPK3 and MLKL in response to necroptotic stimulation. Zharp1-163 markedly attenuates TNF-α (HY-P1875)-induced systemic inflammatory syndrome, including the prevention of TNF-α-induced mortality and hypothermia in mice. Zharp1-163 significantly alleviates acute kidney injury associated with both necroptosis and ferroptosis in models induced by Cisplatin (HY-17394) and ischemia-reperfusion. Zharp1-163 can be used for the study of diseases associated with cell death pathways, such as kidney disease.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Formel: C21H23N5O3
- Molecular Weight:393.44
-
Speicherung:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biologische Aktivität
Beschreibung
IC50 & Target
|
RIPK1 240 nM (Kd) |
RIPK1 406.1 nM (IC50) |
RIPK3 |
In Vitro
Zharp1-163 (0.01-10μM, 18 h) significantly inhibits Erastin (HY-15763)-or RSL3 (HY-100218A)-induced ferroptosis in HT-1080 cells (EC50 = 0.95 μM; EC50 = 1.33 μM) and Mouse Embryonic Fibroblasts (MEFs) (EC50 = 1.93 μM; EC50 = 1.39 μM)[1].
Zharp1-163 (0.01-10 μM, 14-18 h) blocks TNF-α, Smac mimetic, and Z-VAD (HY-164388)-induced necroptosis in HT-29 cells (EC50 = 0.1 μM), and MEFs (EC50 = 0.11 μM)[1].
Zharp1-163 (0.01-10 μM, 14 h) efficiently inhibits TNFα and Z-VAD-induced necroptosis in mouse fibroblast L929 cells[1].
Zharp1-163 (0.3-3 μM, 26 h) inhibits apoptosis induced by TNFα plus Smac mimetic in MEFs[1].
Zharp1-163 (0.3-3 μM, 8 h) does not affect pyroptosis in THP-1 cells[1].
Zharp1-163 (10 μM, 7 h) significantly reduces lipid ROS production during ferroptosis and reduces the induction of both CHAC1 and PTGS2 induced by RSL3 in HT-1080 cells[1].
Zharp1-163 (0.1-3 μM, 10 h) eliminates the phosphorylation of RIPK1, RIPK3, and MLKL in human HT-29 cells and blocks the phosphorylation of RIPK1, RIPK3, and MLKL in MEFs[1].
Zharp1-163 (0.3-3 μM, 10 h) prevents both the generation of RIPK3 puncta and MLKL oligomerization in HT-29 cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:HT-1080 cells and MEFs.
-
Concentration:0.01 μM, 0.1 μM, 1 μM, 10 μM
-
Incubation Time:Pretreated 2 h and then treated with Erastin or RSL3 for 16 h
-
Result:Significantly inhibited Erastin- or RSL3-induced ferroptosis in HT-1080 cells and MEFs.
-
Cell Line:HT-1080 cells and MEFs.
-
Concentration:0.01 μM, 0.1 μM, 1 μM
-
Incubation Time:Pretreated 2 h, followed by treatment with TNF-α (T) (40 ng/mL), Smac mimetic (S) (100 nM), Z-VAD (Z) (20 μM) for 12-16 h
-
Result:Blocked TNF-α, Smac mimetic, and Z-VAD-induced necroptosis in HT-29 cells (EC50 = 0.1 μM), in MEFs (EC50 = 0.11 μM).
-
Cell Line:Mouse fibroblast L929 cells
-
Concentration:0.01 μM, 0.1 μM, 1 μM
-
Incubation Time:2 h, followed by treatment with T (40 ng/mL) and Z (20 μM) for 12 h
-
Result:Blocked TNF-α, Z-VAD-induced necroptosis in mouse fibroblast L929 cells (EC50 = 0.08 μM).
-
Cell Line:MEFs
-
Concentration:0.3 μM, 1 μM, 3 μM
-
Incubation Time:2 h before treatment with T (40 ng/mL) and S (100 nM) for 24 h
-
Result:Inhibited apoptosis induced by TNFα plus Smac mimetic in MEFs.
-
Cell Line:HT-1080 cells
-
Concentration:10 μM
-
Incubation Time:2 h, followed by induction with RSL3 for 5 h
-
Result:Significantly reduced the induction of both CHAC1 and PTGS2 in response to RSL3.
-
Cell Line:HT-29 cells, MEFs
-
Concentration:0.1 μM, 0.3 μM, 1 μM, 3 μM
-
Incubation Time:2 h, followed by treatment with T (40 ng/mL), S (100 nM) and Z (20 μM) for 8 h
-
Result:Eliminated the phosphorylation of RIPK1, RIPK3, and MLKL in human HT-29 cells.
Blocked the phosphorylation of RIPK1, RIPK3, and MLKL in MEFs.
-
Cell Line:HT-29 cells stably expressing Flag-tagged RIPK3
-
Concentration:0.3 μM, 1 μM, 3 μM
-
Incubation Time:Before the addition of T (40 ng/mL), S (100 nM), and Z (20 μM) for an additional 8 h, HT-29 cells stably expressing Flag-tagged RIPK3 were preincubated with the specified compounds for 2 h
-
Result:Prevented the generation of RIPK3 puncta.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6 mice injected TNF[1].
-
Dosage:5 mg/kg
-
Administration:I.p., pretreated with 30 min prior to challenge
-
Result:Significantly protected mice from TNF-α-induced lethality and reduced TNF-α-induced temperature loss in these mice.
Significantly ameliorated the production of proinflammatory cytokines, including IL-6.
Induced damage to the cecum and colon.
-
Animal Model:Cisplatin-induced acute kidney injury in C57BL/6 mice[1].
-
Dosage:5 mg/kg
-
Administration:I.p., pretreated with 30 min prior to challenge
-
Result:Significantly inhibited cisplatin-induced body weight loss.
Mitigated mild inflammation and tubular epithelial cell damage.
Decreased the serum creatinine and blood urea nitrogen (BUN) levels in the context of Cisplatin-induced kidney injury.
-
Animal Model:The left renal artery of C57BL/6 mice pretreated for 2 h was isolated and clamped for 45 min via a nontraumatic artery clamp following right nephrectomy. Reperfusion was subsequently performed[1].
-
Dosage:5 mg/kg
-
Administration:I.p., 2 h
-
Result:Significantly inhibited the levels of creatinine and BUN in mouse serum.
Chemical Information
-
Molecular Weight 393.44
-
Formel C21H23N5O3
-
SMILES
NC1=CN2C(C=CC(C3=CC4=C(N=C3)OCCN4C(OC5CCCCC5)=O)=C2)=N1
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Please store the product under the recommended conditions in the Certificate of Analysis.
Protokoll
-
Kinase activity and phosphorylation assays
Kinase activity assays measure the ability of kinases to transfer phosphate groups from ATP to specific substrates, while phosphorylation assays detect the presence and levels of phosphorylated proteins. Common methods include radiolabeled ATP incorporation (e. g. ,), ADP release detection via bioluminescence (e. g. ,[3]), enzyme-linked immunosorbent assays (ELISA) for phospho-specific epitopes (e. g. ,[6]), and microtiter-based formats for high-throughput screening (e. g. ,[8]). The ADP-Glo assay quantifies kinase activity by measuring ADP produced during phosphorylation using a luciferase-based system. Radiometric assays involve autoradiography or scintillation counting after incorporation of 32P-labeled ATP into substrate proteins. ELISA-based approaches rely on phospho-specific antibodies to detect activated kinases in cell lysates or purified samples.
-
Nephrotoxicity Study
This protocol assesses nephrotoxicity by combining functional kidney injury readouts, urinary/tissue injury biomarkers, and renal histopathology. Serum creatinine and BUN reflect impaired kidney function, while KIM-1, NGAL, clusterin, osteopontin, IL-18, cystatin C, nephrin, Oat5, urinary protein, glucose, and alkaline phosphatase have been used to detect tubular injury in cisplatin-, gentamicin-, and acetaminophen-induced nephrotoxicity models.
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Mammalian live/dead viability and cytotoxicity staining
Live/dead viability and cytotoxicity staining assays are based on the simultaneous detection of intracellular esterase activity in metabolically active (viable) cells and membrane integrity loss in non-viable cells. In commonly used dual-staining approaches, membrane-permeant fluorogenic substrates are converted by intracellular esterases into fluorescent products in live cells, while impermeant DNA-binding dyes selectively enter cells with compromised plasma membranes and label nucleic acids in dead or dying cells, enabling discrimination between viable and non-viable populations by fluorescence microscopy or flow cytometry.
-
ROS/oxidative-stress fluorescent staining
ROS/oxidative-stress fluorescent staining uses cell-permeant fluorogenic probes that become fluorescent after oxidation inside cells or tissues; commonly used examples include DCFH-DA/DCFDA for broad cellular oxidant detection, DHE for superoxide-related signal detection, MitoSOX for mitochondrial superoxide-related signal detection, and CellROX probes for oxidative-stress-associated fluorescence readouts. The assay detects probe oxidation rather than a single ROS species unless the probe and analysis method have been chemically validated for that species. DCFH-DA enters cells, is deacetylated by intracellular esterases to DCFH, and produces fluorescent DCF after oxidation, so the readout is used as an operational measure of total cellular oxidative stress rather than a species-specific ROS measurement. DHE and MitoSOX can report superoxide-related oxidation, but red fluorescence alone can include non-specific ethidium-like oxidation products; HPLC or optimized spectral approaches are
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Ferroptosis Solutions
Ferroptosis is an iron-dependent, non-apoptotic form of regulated cell death characterized by lethal lipid peroxidation and sensitivity to suppression by iron chelators or lipophilic radical-trapping antioxidants. The core pathway links cystine uptake through system Xc−, glutathione availability, GPX4-dependent detoxification of phospholipid hydroperoxides, iron-dependent oxidative reactions, and polyunsaturated-phospholipid metabolism into a cell-death program that is biochemically and morphologically distinct from apoptosis, necrosis, and autophagy. The ferroptosis pathway is experimentally linked to phenotype through chemical and genetic perturbation. Erastin induces ferroptosis by inhibiting cystine uptake through system Xc− and weakening antioxidant defenses, while GPX4 inhibition or depletion causes lipid peroxide accumulation and ferroptotic cancer-cell death. ACSL4 and oxidizable arachidonoyl- or adrenoyl-containing phosphatidylethanolamines shape ferroptosis sensitivity by con
-
Protocol for Kinase activity and phosphorylation assays
Kinase activity assays measure transfer of phosphate from ATP to a protein or peptide substrate, generating phosphorylated substrate, ADP, or incorporated radiolabeled phosphate as the readout; phosphorylation assays measure site-specific phosphorylation in cells or tissues as a proxy for kinase-pathway activation, inhibition, or substrate regulation. Phosphorylation can be detected by phospho-specific Western blot, immunoprecipitation kinase assay, phospho-immunofluorescence, phospho-flow cytometry, luminescent ADP detection, radiolabeled ATP incorporation, or reporter-based pathway assays, and these readouts can be applied to cancer cells, primary neurons, mouse tumors, organoids, inflammatory macrophages, ferroptosis studies, and mitophagy studies when the kinase target is biologically relevant.
Reinheit & Dokumentation
Verweise
Calculators
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)